文献速递生殖医学母胎医学

无创植入前遗传学检测(niPGT):生殖遗传学的下一次革命?

Non-invasive preimplantation genetic testing (niPGT): the next revolution in reproductive genetics?
PubMed 文献 · Hum Reprod Update · 2020-01-01

本文综述无创植入前遗传学检测(niPGT)的科学证据,评估囊胚腔液(BF)和废弃胚胎培养液(SCM)中胚胎DNA的采集与分析效果。胚DNA常可检测,但受DNA低量与低质限制,倍性一致率变异大,可能受嵌合体或污染影响。现有数据显示BF和SCM样本常提供可用DNA模板,但临床潜力仍未知。

要点

  • BF和SCM中常可检测到胚胎DNA,初步研究在细胞遗传和分子遗传分析中取得一定成功。
  • DNA低量和低质导致技术困难,SCM/BF样本与活检胚胎细胞的倍性一致率报道差异大。
  • 倍性不一致可能源于胚胎嵌合体或DNA污染(通常为母源),非整倍体细胞可能优先被清除的假说需进一步研究。

核心结论

  • 现有数据提示BF和SCM样本常提供适合遗传分析的DNA模板,可能成为比传统方法更便宜、所需显微操作技能更少且对胚胎风险更低的PGT手段。
  • 关键需优化DNA分离和扩增方案以可重复地获得准确临床诊断,同时最小化污染等混杂因素的影响。
  • 需进一步研究以理解胚胎DNA释放机制及该物质反映相应胚胎真实遗传状态的程度,目前niPGT的临床潜力仍未知。

研究设计与样本

  • 综述,检索PubMed和Google Scholar数据库至2019年7月,纳入关于niPGT的原创研究和综述论文。
  • 检索关键词包括non-invasive、cell-free DNA、blastocentesis、blastocoel fluid、spent culture media、embryo culture medium、preimplantation genetic testing、preimplantation genetic diagnosis、preimplantation genetic screening和aneuploidy。

主要发现

  • 在IVF治疗产生的胚胎的BF和SCM中常可检测到胚胎DNA,初步研究在细胞遗传和分子遗传分析中取得一定成功。
  • 许多情况下,DNA低量和低质相关的技术并发症限制了效率,SCM/BF样本与活检胚胎细胞之间的倍性一致率报道水平差异很大。
  • 某些情况下,与滋养外胚层活检后获得的细胞遗传数据不一致可能归因于胚胎嵌合体或DNA污染(通常为母源)。
  • 一些研究表明非整倍体细胞优先从胚胎中清除,提示其DNA可能在SCM和BF样本中过度代表;该假说需进一步研究。

临床怎么用

  • 现有数据提示BF和SCM样本常提供适合遗传分析的DNA模板,可能成为比传统方法更便宜、所需显微操作技能更少且对胚胎风险更低的PGT手段。
  • 关键需优化DNA分离和扩增方案以可重复地获得准确临床诊断,同时最小化污染等混杂因素的影响。
  • 需进一步研究以理解胚胎DNA释放机制及该物质反映相应胚胎真实遗传状态的程度,目前niPGT的临床潜力仍未知。

局限性

  • 许多情况下,DNA低量和低质相关的技术并发症限制了效率。
  • SCM/BF样本与活检胚胎细胞之间的倍性一致率报道水平差异很大。
  • 与滋养外胚层活检后获得的细胞遗传数据不一致可能归因于胚胎嵌合体或DNA污染(通常为母源)。
  • 非整倍体细胞优先从胚胎中清除的假说需进一步研究。
  • 需进一步研究以理解胚胎DNA释放机制及该物质反映相应胚胎真实遗传状态的程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preimplantation genetic testing (PGT) encompasses methods that allow embryos to be tested for severe inherited conditions or for chromosome abnormalities, relevant to embryo health and viability. In order to obtain embryonic genetic material for analysis, a biopsy is required, involving the removal of one or more cells. This invasive procedure greatly increases the costs of PGT and there have been concerns that embryo viability could be compromised in some cases. The recent discovery of DNA within the blastocoele fluid (BF) of blastocysts and in spent embryo culture media (SCM) has led to interest in the development of non-invasive methods of PGT (niPGT). OBJECTIVE AND RATIONALE: This review evaluates the current scientific evidence regarding non-invasive genetic assessment of preimplantation embryos. The success of different PGT methodologies in collecting and analysing extra-embryonic DNA is evaluated, and consideration is given to the potential biological and technical hindrances to obtaining a reliable clinical diagnosis. SEARCH METHODS: Original research and review papers concerning niPGT were sourced by searching PubMed and Google Scholar databases until July 2019. Searches comprised the keywords: 'non-invasive'; 'cell-free DNA'; 'blastocentesis'; 'blastocoel fluid'; 'spent culture media'; 'embryo culture medium'; 'preimplantation genetic testing'; 'preimplantation genetic diagnosis'; 'preimplantation genetic screening'; and 'aneuploidy'. OUTCOMES: Embryonic DNA is frequently detectable in BF and SCM of embryos produced during IVF treatment. Initial studies have achieved some success when performing cytogenetic and molecular genetic analysis. However, in many cases, the efficiency has been restricted by technical complications associated with the low quantity and quality of the DNA. Reported levels of ploidy agreement between SCM/BF samples and biopsied embryonic cells vary widely. In some cases, a discrepancy with respect to cytogenetic data obtained after trophectoderm biopsy may be attributable to embryonic mosaicism or DNA contamination (usually of maternal origin). Some research indicates that aneuploid cells are preferentially eliminated from the embryo, suggesting that their DNA might be over-represented in SCM and BF samples; this hypothesis requires further investigation. WIDER IMPLICATIONS: Available data suggest that BF and SCM samples frequently provide DNA templates suitable for genetic analyses, offering a potential means of PGT that is less expensive than traditional methods, requires less micromanipulation skill and poses a lower risk to embryos. Critically, DNA isolation and amplification protocols must be optimised to reproducibly obtain an accurate clinical diagnosis, whilst minimising the impact of confounding factors such as contamination. Further investigations are required to understand the mechanisms underlying the release of embryonic DNA and to determine the extent to which this material reflects the true genetic status of the corresponding embryo. Currently, the clinic al potential of niPGT remains unknown.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Leaver M, Wells D. Non-invasive preimplantation genetic testing (niPGT): the next revolution in reproductive genetics? Hum Reprod Update. 2020. PMID: 31774124. doi:10.1093/humupd/dmz033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。